Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Featured trial
NN2211-4232 LIRA-PRIME: Efficacy in controlling glycaemia with Victoza (liraglutide) as add-on to metformin vs. OAD's as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting.

NN2211-4232 LIRA-PRIME: Efficacy in controlling glycaemia with Victoza (liraglutide) as add-on to metformin vs. OAD's as add-on to metformin after up to 104 weeks of treatment in subjects with type 2

  • 495 views
  • 25 Mar, 2021
  • 1 location
Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes" (TOLEDDO)

, the most recent and most potent GLP1 agonist (superiority demonstrated compared to exenatide LP and dulaglutide) and administered as a weekly subcutaneous injection (in contrast to liraglutide

  • 0 views
  • 04 Oct, 2022
  • 1 location
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke

  • 0 views
  • 17 Feb, 2021
  • 1 location
Liraglutide Effect in Atrial Fibrillation (LEAF)

amount of EAT, this study will use a medication called Liraglutide. This medication is known to work on fat deposits and produce weight loss. The investigator is conducting this study to find out if

antiarrhythmic drug
amiodarone
fibrillation
persistent atrial fibrillation
hypertension
  • 29 views
  • 14 May, 2022
  • 1 location
Liraglutide Effects on Epicardial Fat Inflammatory Genes

serves as target for medications targeting the fat. Glucagon-like peptide-1 agonists (GLP-1A) are anti-diabetic medications with recently suggested cardio-protective properties. Liraglutide, a GLP-1A

bypass graft
heart surgery
arterial disease
  • 7 views
  • 12 Feb, 2022
  • 1 location
Efficacy of Liraglutide Therapy in Patients With IPAA

randomized to liraglutide or placebo in a prospective cross over study.

  • 0 views
  • 14 Apr, 2022
  • 1 location
Effects of LIraglutide on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging (LICAS-MR)

processes. It has also been demonstrated in a diabetic rat model that the administration of Liraglutide, a GLP-1 agonist, leads to normalization of myocardial steatosis associated with beneficial cardiac

glucagon-like peptide-1
hypertension
glucagon
glucagon-like peptide 1
liraglutide
  • 0 views
  • 07 Apr, 2022
  • 1 location
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes (Liragest)

' liraglutide treatment could decrease the risk of T2D in obese women who have had gestational diabetes. The women are randomized either to liraglutide (Victoza ® 1.8 mg) or placebo group, once daily. Same

metformin
Accepts healthy volunteers
diabetes
liraglutide
type 2 diabetes mellitus
  • 1 views
  • 23 May, 2022
  • 1 location
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

The aim of the trail is investigate the effect of liraglutide 1.8mg as add-on to insulin for 6 months on carotid intima media thickness and cardiovascular risk factors in subjects with type 1

  • 0 views
  • 04 Oct, 2022
The Effect of Different Diets on Arterial Stiffness in Obese Patients on Liraglutide

In patients initiating Liraglutide for weight management, the objective is to compare the effect of Med diet, high protein/low carbohydrate (HP/LC) diet and low fat (LF) control diet on CV

fats
liraglutide
Accepts healthy volunteers
weight control
  • 0 views
  • 04 Oct, 2022
  • 1 location